Belarus Launches Biopharmaceutical Project to Replace Imports
A new biopharmaceutical production project is set to commence in Belarus, based on 'BelVitunifarm'. The project aims to replace imports and is backed by a significant investment. The investor's name is not publicly known at this time.
The project, facilitated by Decree No.346 signed by Alexander Lukashenko, will establish capacities for veterinary and medical drugs at OJSC 'BelVitunifarm'. The investor will gain the right to necessary land plots for construction and maintenance of project facilities. The enterprise will also shed non-core assets, transferring them to municipal ownership.
The project enjoys favourable conditions. For two years post-completion, special sales terms are set for products. Additionally, the investor can utilise technological and other equipment previously acquired under Decree No.430. To purchase veterinary and medical drugs, interested parties can do so directly from the enterprise, following a single-source procurement procedure with a certificate of own production.
The biopharmaceutical production project at 'BelVitunifarm' is poised to boost Belarus' import substitution efforts. Despite the unknown investor, the project benefits from state support and advantageous conditions. Upon completion, it will facilitate direct procurement of veterinary and medical drugs.
Read also:
- Aquatech purchases Koch's Direct Lithium Extraction business, merging Li-ProTM DLE technology into the PEARLTM Technology Platform.
- Li Auto faces scrutiny after crash test involving i8 model and a truck manufacturer sparks controversy
- Emerging Investment Trends in China's Ethical Finance Sector for 2025
- Construction and renovation projects in Cham county granted €24.8 million focus on energy efficiency
